Literature DB >> 27272044

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

M E G Naranjo1, F de Andrés1, A Delgado1, J Cobaleda1,2, E M Peñas-Lledó1, A LLerena1,3.   

Abstract

A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has been claimed to exist among Spaniards and Southern Europeans. However, methodological aspects such as the inclusion of individuals carrying non-active multiplied alleles as gUMs may have led to an overestimation. Thus, this study aimed to analyze the gUM frequency (considering only those carrying more than two active genes) in 805 Spanish healthy volunteers studied for CYP2D6*2, *3, *4, *5, *6, *10, *17, *35, *41, and multiplications. Second, all worldwide studies reporting gUM frequencies were reviewed in order to evaluate potential misclassifications. The gUM frequency in this Spanish population was 5.34%, but increased to 8.3% if all individuals with CYP2D6 multiplications were classified as gUMs without considering the activity of the multiplied alleles. Moreover, among all reviewed worldwide studies only 55.6% precisely determined whether the multiplied alleles were active. Present results suggest that the evaluation of CYP2D6 ultrarapid metabolism should be standarized, and that the frequency of gUMs should be reconsidered in Spaniards and globally.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27272044     DOI: 10.1038/tpj.2016.47

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  67 in total

1.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Authors:  Maria Gabriella Scordo; Achille P Caputi; Concetta D'Arrigo; Giuseppina Fava; Edoardo Spina
Journal:  Pharmacol Res       Date:  2004-08       Impact factor: 7.658

2.  High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

Authors:  A L Zackrisson; B Lindblom; J Ahlner
Journal:  Clin Pharmacol Ther       Date:  2009-11-11       Impact factor: 6.875

3.  CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico.

Authors:  Blanca Patricia Lazalde-Ramos; Margarita de la Luz Martínez-Fierro; Carlos Galaviz-Hernández; Idalia Garza-Veloz; María Eugenia G Naranjo; Martha Sosa-Macías; Adrián Llerena
Journal:  Pharmacogenomics       Date:  2014-02       Impact factor: 2.533

4.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.

Authors:  E Aklillu; I Persson; L Bertilsson; I Johansson; F Rodrigues; M Ingelman-Sundberg
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

5.  Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.

Authors:  C A Isaza; J Henao; A M López; R Cacabelos
Journal:  Methods Find Exp Clin Pharmacol       Date:  2000-11

6.  CYP2D6 genotyping by liquid chromatography-electrospray ionization mass spectrometry.

Authors:  Beate Beer; Robert Erb; Florian Pitterl; Harald Niederstätter; Olalla Maroñas; Alejandro Gesteira; Angel Carracedo; Irina Piatkov; Herbert Oberacher
Journal:  Anal Bioanal Chem       Date:  2011-01-12       Impact factor: 4.142

7.  Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.

Authors:  R A McLellan; M Oscarson; J Seidegård; D A Evans; M Ingelman-Sundberg
Journal:  Pharmacogenetics       Date:  1997-06

8.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

9.  CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

Authors:  Thomas Rau; Gerlinde Wohlleben; Henrike Wuttke; Norbert Thuerauf; Jens Lunkenheimer; Mario Lanczik; Thomas Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

10.  Characterization of pharmacogenetically relevant CYP2D6 and ABCB1 gene polymorphisms in a Portuguese population sample.

Authors:  C Correia; P Santos; A M Coutinho; A M Vicente
Journal:  Cell Biochem Funct       Date:  2009-06       Impact factor: 3.685

View more
  4 in total

1.  Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Authors:  Waheed Adeola Adedeji; Sharon Iyobor Igbinoba; Titilayo O Fakeye; Ibrahim Adebayo Oladosu; Fatai Adewale Fehintola; Qing Ma; Gene D Morse
Journal:  Expert Rev Clin Pharmacol       Date:  2017-08-30       Impact factor: 5.045

2.  Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers.

Authors:  Maria J Arranz; Juliana Salazar; Valentin Bote; Alicia Artigas-Baleri; Alexandre Serra-LLovich; Emma Triviño; Jordi Roige; Carlos Lombardia; Martha Cancino; Marta Hernandez; Marc Cendros; Enric Duran-Tauleria; Natalia Maraver; Amaia Hervas
Journal:  Pharmaceutics       Date:  2022-05-06       Impact factor: 6.525

3.  Multiple adverse drug reactions and genetic polymorphism testing: A case report with negative result.

Authors:  Ana Lucía Arellano; Marta Martin-Subero; Mar Monerris; Adrián LLerena; Magí Farré; Eva Montané
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

4.  A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments.

Authors:  Maria J Arranz; Alex Gonzalez-Rodriguez; Josefina Perez-Blanco; Rafael Penadés; Blanca Gutierrez; Laura Ibañez; Barbara Arias; Mercè Brunet; Jorge Cervilla; Juliana Salazar; Rosa Catalan
Journal:  Transl Psychiatry       Date:  2019-07-25       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.